<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280473</url>
  </required_header>
  <id_info>
    <org_study_id>11193X-001</org_study_id>
    <nct_id>NCT02280473</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients
      with dry eye disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2014</start_date>
  <completion_date type="Actual">March 16, 2015</completion_date>
  <primary_completion_date type="Actual">March 16, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score</measure>
    <time_frame>Baseline, Day 30</time_frame>
    <description>The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the OSDI© Score</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tear Break-up Time (TBUT)</measure>
    <time_frame>Baseline, Day 30</time_frame>
    <description>TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement). The eye with shorter average TBUT at baseline is reported for each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Combined Corneal and Conjunctival Staining Scores</measure>
    <time_frame>Baseline, Day 30</time_frame>
    <description>The cornea is the transparent front part of the eye which covers the iris and pupil. The conjunctiva is the clear membrane covering the white surface of the eye. The cornea is divided into 5 zones and the nasal and temporal conjunctiva is divided into 6 zones. The combined staining score is based on the sum of the five zones on the cornea and the six zones on the conjunctiva. Each zone is graded on a 0-5 scale (0=None; 1=trace; 2=mild; 3=moderate; 4=severe; 5=very severe), for a total score ranging from 0-55. The higher the score, the worse the dry eye condition. A negative number change from baseline represents a decrease in the severity of staining (improvement). The eye with higher score at baseline is reported for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Schirmer Test</measure>
    <time_frame>Baseline, Day 30</time_frame>
    <description>The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye. The eye with the lower value at Baseline was used for Analysis. Normal = greater than or equal to 15 millimeters (mm) of tears, Dry Eye = less than 15 mm of tears.. The smaller the number, the more severe the dry eye. A positive number change from Baseline indicates improvement. The eye with the lower value at baseline is used for each subject.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Refresh Optive® Gel Drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REFRESH LIQUIGEL®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Refresh Optive® Gel Drops</intervention_name>
    <description>Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
    <arm_group_label>Refresh Optive® Gel Drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REFRESH LIQUIGEL®</intervention_name>
    <description>REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
    <arm_group_label>REFRESH LIQUIGEL®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current use of an artificial tear product

          -  Visual acuity of at least 20/32 (while wearing glasses, if necessary).

        Exclusion Criteria:

          -  Use of contact lenses in the last 3 months, or anticipated use of contact lenses
             during the study

          -  Cataract surgery, laser-assisted in situ keratomileusis [LASIK], or photorefractive
             keratectomy, within the last 6 months

          -  Current eye infection or inflammation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Bay Eye Associates</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eric M. White, OD, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Center Northeast</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moyes Eye Center, PC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Eye Care, Ltd.</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Ophthalmological Group, PC</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David W. Ferris &amp; Associates, Inc.</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02888</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Eyecare Group, PC</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Center at Southern College of Optometry</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <results_first_submitted>May 12, 2017</results_first_submitted>
  <results_first_submitted_qc>May 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2017</results_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Refresh Optive® Gel Drops</title>
          <description>Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
        </group>
        <group group_id="P2">
          <title>REFRESH LIQUIGEL®</title>
          <description>REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 188 randomized patients were included in the Intent-to Treat (ITT) and safety populations.</population>
      <group_list>
        <group group_id="B1">
          <title>Refresh Optive® Gel Drops</title>
          <description>Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
        </group>
        <group group_id="B2">
          <title>REFRESH LIQUIGEL®</title>
          <description>REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to less than 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score</title>
        <description>The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
        <time_frame>Baseline, Day 30</time_frame>
        <population>Intent-to-Treat: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Refresh Optive® Gel Drops</title>
            <description>Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>REFRESH LIQUIGEL®</title>
            <description>REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score</title>
          <description>The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
          <population>Intent-to-Treat: All randomized patients</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.44" spread="11.708"/>
                    <measurement group_id="O2" value="40.43" spread="11.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.29" spread="15.864"/>
                    <measurement group_id="O2" value="-7.48" spread="16.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the OSDI© Score</title>
        <description>The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Intent-to-Treat: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Refresh Optive® Gel Drops</title>
            <description>Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>REFRESH LIQUIGEL®</title>
            <description>REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the OSDI© Score</title>
          <description>The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
          <population>Intent-to-Treat: All randomized patients</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.44" spread="11.708"/>
                    <measurement group_id="O2" value="40.43" spread="11.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.74" spread="14.338"/>
                    <measurement group_id="O2" value="-2.34" spread="12.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tear Break-up Time (TBUT)</title>
        <description>TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement). The eye with shorter average TBUT at baseline is reported for each patient.</description>
        <time_frame>Baseline, Day 30</time_frame>
        <population>Intent-to-Treat: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Refresh Optive® Gel Drops</title>
            <description>Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>REFRESH LIQUIGEL®</title>
            <description>REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tear Break-up Time (TBUT)</title>
          <description>TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement). The eye with shorter average TBUT at baseline is reported for each patient.</description>
          <population>Intent-to-Treat: All randomized patients</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" spread="1.674"/>
                    <measurement group_id="O2" value="5.40" spread="2.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 30 (N-94, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="1.968"/>
                    <measurement group_id="O2" value="0.70" spread="4.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Combined Corneal and Conjunctival Staining Scores</title>
        <description>The cornea is the transparent front part of the eye which covers the iris and pupil. The conjunctiva is the clear membrane covering the white surface of the eye. The cornea is divided into 5 zones and the nasal and temporal conjunctiva is divided into 6 zones. The combined staining score is based on the sum of the five zones on the cornea and the six zones on the conjunctiva. Each zone is graded on a 0-5 scale (0=None; 1=trace; 2=mild; 3=moderate; 4=severe; 5=very severe), for a total score ranging from 0-55. The higher the score, the worse the dry eye condition. A negative number change from baseline represents a decrease in the severity of staining (improvement). The eye with higher score at baseline is reported for each subject.</description>
        <time_frame>Baseline, Day 30</time_frame>
        <population>Intent-to-Treat: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Refresh Optive® Gel Drops</title>
            <description>Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>REFRESH LIQUIGEL®</title>
            <description>REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Combined Corneal and Conjunctival Staining Scores</title>
          <description>The cornea is the transparent front part of the eye which covers the iris and pupil. The conjunctiva is the clear membrane covering the white surface of the eye. The cornea is divided into 5 zones and the nasal and temporal conjunctiva is divided into 6 zones. The combined staining score is based on the sum of the five zones on the cornea and the six zones on the conjunctiva. Each zone is graded on a 0-5 scale (0=None; 1=trace; 2=mild; 3=moderate; 4=severe; 5=very severe), for a total score ranging from 0-55. The higher the score, the worse the dry eye condition. A negative number change from baseline represents a decrease in the severity of staining (improvement). The eye with higher score at baseline is reported for each subject.</description>
          <population>Intent-to-Treat: All randomized patients</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="7.24"/>
                    <measurement group_id="O2" value="11.8" spread="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 30 (N=93, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="4.66"/>
                    <measurement group_id="O2" value="-2.0" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Schirmer Test</title>
        <description>The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye. The eye with the lower value at Baseline was used for Analysis. Normal = greater than or equal to 15 millimeters (mm) of tears, Dry Eye = less than 15 mm of tears.. The smaller the number, the more severe the dry eye. A positive number change from Baseline indicates improvement. The eye with the lower value at baseline is used for each subject.</description>
        <time_frame>Baseline, Day 30</time_frame>
        <population>Intent-to-Treat: All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Refresh Optive® Gel Drops</title>
            <description>Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>REFRESH LIQUIGEL®</title>
            <description>REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Schirmer Test</title>
          <description>The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye. The eye with the lower value at Baseline was used for Analysis. Normal = greater than or equal to 15 millimeters (mm) of tears, Dry Eye = less than 15 mm of tears.. The smaller the number, the more severe the dry eye. A positive number change from Baseline indicates improvement. The eye with the lower value at baseline is used for each subject.</description>
          <population>Intent-to-Treat: All randomized patients</population>
          <units>mm/5 min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.98" spread="7.178"/>
                    <measurement group_id="O2" value="11.32" spread="8.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 30 (N=88, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="5.601"/>
                    <measurement group_id="O2" value="0.69" spread="6.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from Screening through Day 30.</time_frame>
      <desc>The Safety Population included all patients who received at least 1 dose of the study treatment. The Safety Population was used to assess adverse events and serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Refresh Optive® Gel Drops</title>
          <description>Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
        </group>
        <group group_id="E2">
          <title>REFRESH LIQUIGEL®</title>
          <description>REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hyphaema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Robinson</name_or_title>
      <organization>Allergan plc</organization>
      <phone>1-714-246-6415</phone>
      <email>Robinson_Michael@Allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

